Fatty acids, eicosanoids and cancer

Nutritional Therapy and Metabolism

Volumn 27, Issue 3, 2009, Pages 105-112

  Colquhoun, A ^a   Miyake, J A ^a   Benadiba, M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cancer; Eicosanoids; Fatty acids; Glioma; Prostaglandins

Indexed keywords

ANIMALIA;

EID: 73649099836     PISSN: 18286232     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Sprecher H. Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim Biophys Acta 2000; 1486: 219-31.
2. Smith WL. Nutritionally essential fatty acids and biologically indispensable cyclooxygenases. Trends Biochem Sci 2008; 33: 27-37.
3. Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999; 83: 217-44.
4. Nkondjock A, Shatenstein B, Maisonneuve P, Ghadirian P. Specific fatty acids and human colorectal cancer: an overview. Cancer Detect Prev 2003; 27: 55-66.
5. Simopoulos AP. The Mediterranean diets: What is so special about the diet of Greece? The scientific evidence. J Nutr 2001; 131 (11 Suppl): 3065S-73S.
6. Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature 2009; 458: 725-31.
7. Buckley JD, Howe PR. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes Rev 2009 May 12 [Epub ahead of print].
8. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993; 85: 1819-27.
9. Hillyard LA, Abraham S. Effect of dietary polyunsaturated fatty acids on growth of mammary adenocarcinomas in mice and rats. Cancer Res 1979; 39: 4430-7.
10. Abraham S, Hillyard LA. Effect of dietary 18-carbon fatty acids on growth of transplantable mammary adenocarcinomas in mice. J Natl Cancer Inst 1983; 71: 601-5.
11. Welsch CW. Relationship between dietary fat and experimental mammary tumorigenesis: a review and critique. Cancer Res 1992; 52 (7 Suppl): 2040s-8s.
12. Sauer LA, Dauchy RT, Blask DE. Mechanism for the antitumor and anticachectic effects of n-3 fatty acids. Cancer Res 2000; 60: 5289-95.
13. Sauer LA, Blask DE, Dauchy RT. Dietary factors and growth and metabolism in experimental tumors. J Nutr Biochem 2007; 18: 637-49.
14. Rose DP, Connolly JM. Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice. J Natl Cancer Inst 1993; 85: 1743-7.
15. Cohen LA, Chen-Backlund JY, Sepkovic DW, Sugie S. Effect of varying proportions of dietary menhaden and corn oil on experimental rat mammary tumor promotion. Lipids 1993; 28: 449-56.
16. Gonzalez MJ, Schemmel RA, Dugan L Jr, Gray JI, Welsch CW. Dietary fish oil inhibits human breast carcinoma growth: a function of increased lipid peroxidation. Lipids 1993; 28: 827-32.
17. Chapkin RS, McMurray DN, Lupton JR. Colon cancer, fatty acids and anti-inflammatory compounds. Curr Opin Gastroenterol 2007; 23: 48-54.
18. Rose DP, Connolly JM, Liu XH. Fatty acid regulation of breast cancer cell growth and invasion. Adv Exp Med Biol 1997; 422: 47-55.
19. Bégin ME, Ells G, Das UN, Horrobin DF. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst 1986; 77: 1053-62.
20. Bégin ME, Ells G, Horrobin DF. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J Natl Cancer Inst 1988; 80: 188-94.
21. Lai PB, Ross JA, Fearon KC, Anderson JD, Carter DC. Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro. Br J Cancer 1996; 74: 1375-83.
22. Hawkins RA, Sangster K, Arends MJ. Apoptotic death of pancreatic cancer cells induced by polyunsaturated fatty acids varies with double bond number and involves an oxidative mechanism. J Pathol 1998; 185: 61-70.
23. Hrelia S, Pession A, Buda R, et al. Concentration-and time-dependent effects of gamma-linolenic acid supplementation to tumor cells in culture. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 235-41.
24. Colquhoun A, Schumacher RI. Modifications in mitochondrial metabolism and ultrastructure and their relationship to tumour growth inhibition by gamma-linolenic acid. Mol Cell Biochem 2001; 218: 13-20.
25. Colquhoun A. Gamma-linolenic acid alters the composition of mitochondrial membrane subfractions, decreases outer mitochondrial membrane binding of hexokinase and alters carnitine palmitoyltransferase I properties in the Walker 256 rat tumour. Biochim Biophys Acta 2002; 1583: 74-84.
26. Leaver HA, Wharton SB, Bell HS, Leaver-Yap IM, Whittle IR. Highly unsaturated fatty acid induced tumour regression in glioma pharmacodynamics and bioavailability of gamma linolenic acid in an implantation glioma model: effects on tumour biomass, apoptosis and neuronal tissue histology. Prostaglandins Leukot Essent Fatty Acids 2002; 67: 283-92.
27. Miyake JA, Benadiba M, Colquhoun A. Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression. Lipids Health Dis 2009; 8: 8.
28. Das UN, Prasad VV, Reddy DR. Local application of gamma-linolenic acid in the treatment of human gliomas. Cancer Lett 1995; 94: 147-55.
29. Bakshi A, Mukherjee D, Bakshi A, Banerji AK, Das UN. Gamma-linolenic acid therapy of human gliomas. Nutrition 2003; 19: 305-9. Comment on: Nutrition 2003; 19: 386-8.
30. Das UN. From bench to the clinic: gamma-linolenic acid therapy of human gliomas. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 539-52.
31. Das UN. Gamma-linolenic acid therapy of human glioma--a review of in vitro, in vivo, and clinical studies. Med Sci Monit 2007; 13: RA119-31.
32. Kenny FS, Pinder SE, Ellis IO, et al. Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. Int J Cancer 2000; 85: 643-8.
33. Harris NM, Crook TJ, Dyer JP, et al. Intravesical meglumine gamma-linolenic acid in superficial bladder cancer: an efficacy study. Eur Urol 2002; 42: 39-42.
34. Harris NM, Anderson WR, Lwaleed BA, Cooper AJ, Birch BR, Solomon LZ. Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma. Cancer 2003; 97: 71-8.
35. Mackie SJ, Sharma DM, Cooper AJ, Harris NM, Lwaleed BA. Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 367-73.
36. Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 2008; 269: 363-77.
37. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2: 879-90.
38. Masoodi M, Nicolaou A. Lipidomic analysis of twenty-seven prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 2006; 20: 3023-9.
39. Romano M, Claria J. Cyclooxygenase-2 and 5-lipo-xygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003; 17: 1986-95.
40. Nathoo N, Barnett GH, Golubic M. The eicosanoid cascade: possible role in gliomas and meningiomas. J Clin Pathol 2004; 57: 6-13.
41. Fürstenberger G, Krieg P, Müller-Decker K, Habenicht AJ. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 2006; 119: 2247-54.
42. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A. Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol 2008; 89: 73-87.
43. Dommels YE, Haring MM, Keestra NG, Alink GM, van Bladeren PJ, van Ommen B. The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis 2003; 24: 385-92.
44. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008; 47: 147-55.
45. Masoodi M, Mir AA, Petasis NA, Serhan CN, Nicolaou A. Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom 2008; 22: 75-83.
46. Sauer LA, Dauchy RT, Blask DE. Dietary linoleic acid intake controls the arterial blood plasma concentration and the rates of growth and linoleic acid uptake and metabolism in hepatoma 7288CTC in Buffalo rats. J Nutr 1997; 127: 1412-21.
47. Sauer LA, Dauchy RT, Blask DE, Armstrong BJ, Scalici S.13-Hydroxyoctadecadienoic acid is the mitogenic signal for linoleic acid-dependent growth in rat hepatoma 7288CTC in vivo. Cancer Res 1999; 59: 4688-92.
48. Kelavkar UP, Hutzley J, Dhir R, Kim P, Allen KG, McHugh K. Prostate tumor growth and recurrence can be modulated by the omega-6: omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. Neoplasia 2006; 8: 112-24.
49. Calder PC. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 327-35.
50. Chapkin RS, Seo J, McMurray DN, Lupton JR. Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine. Chem Phys Lipids 2008; 153: 14-23.
51. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349-61.
52. Schäfer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008; 9: 628-38.
53. Calder PC. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 2008; 52: 885-97.
54. Tang DG, Bhatia B, Tang S, Schneider-Broussard R. 15-lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins Other Lipid Mediat 2007; 82: 135-46.
55. Vang K, Ziboh VA. 15-lipoxygenase metabolites of gamma-linolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 363-72.
56. Pham H, Vang K, Ziboh VA. Dietary gamma-linolenate attenuates tumor growth in a rodent model of prostatic adenocarcinoma via suppression of elevated generation of PGE(2) and 5S-HETE. Prostaglandins Leukot Essent Fatty Acids 2006; 74: 271-82.
57. Serini S, Piccioni E, Merendino N, Calviello G. Dietary polyunsaturated fatty acids as inducers of apoptosis: implications for cancer. Apoptosis 2009; 14: 135-52.
58. Jiang WG, Bryce RP, Horrobin DF. Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. Crit Rev Oncol Hematol 1998; 27: 179-209.
59. Dupertuis YM, Meguid MM, Pichard C. Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 2007; 10: 427-32.
60. Colquhoun A, Schumacher RI. gamma-Linolenic acid and eicosapentaenoic acid induce modifications in mitochondrial metabolism, reactive oxygen species generation, lipid peroxidation and apoptosis in Walker 256 rat carcinosarcoma cells. Biochim Biophys Acta 2001; 1533: 207-19.
61. Colquhoun A. Mechanisms of action of eicosapentaenoic acid in bladder cancer cells in vitro: alterations in mitochondrial metabolism, reactive oxygen species generation and apoptosis induction. J Urol 2009; 181: 1885-93.
62. Calviello G, Palozza P, Piccioni E, et al. Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: effects on proliferation and apoptosis. Int J Cancer 1998; 75: 699-705.
63. Colquhoun A, Ramos KL, Schumacher RI. Eicosapentaenoic acid and docosahexaenoic acid effects on tumour mitochondrial metabolism, acyl CoA metabolism and cell proliferation. Cell Biochem Funct 2001; 19: 97-105.
64. Vartak S, McCaw R, Davis CS, Robbins ME, Spector AA. Gamma-linolenic acid (GLA) is cytotoxic to 36B10 malignant rat astrocytoma cells but not to 'normal' rat astrocytes. Br J Cancer 1998; 77: 1612-20.
65. Vartak S, Robbins ME, Spector AA. The selective cytotoxicity of gamma-linolenic acid (GLA) is associated with increased oxidative stress. Adv Exp Med Biol 1999; 469: 493-8.
66. Bell HS, Wharton SB, Leaver HA, Whittle IR. Effects of N-6 essential fatty acids on glioma invasion and growth: experimental studies with glioma spheroids in collagen gels. J Neurosurg 1999; 91: 989-96.
67. Leaver HA, Williams JR, Ironside JW, et al. Dynamics of reactive oxygen intermediate production in human glioma: n-6 essential fatty acid effects. Eur J Clin Invest 1999; 29: 220-31. Comment in: Eur J Clin Invest 1999; 29: 185-8.
68. Ramos KL, Colquhoun A. Protective role of glucose-6-phosphate dehydrogenase activity in the metabolic response of C6 rat glioma cells to polyunsaturated fatty acid exposure. Glia 2003; 43: 149-66.
69. Benadiba M, Miyake JA, Colquhoun A. Gamma-linolenic acid alters Ku80, E2F1, and bax expression and induces micronucleus formation in C6 glioma cells in vitro. IUBMB Life 2009; 61: 244-51.
70. Colquhoun A, de Mello FE, Curi R. Regulation of tumour cell fatty acid oxidation by n-6 polyunsaturated fatty acids. Biochem Mol Biol Int 1998; 44: 143-50.
71. Colquhoun A. Induction of apoptosis by polyunsaturated fatty acids and its relationship to fatty acid inhibition of carnitine palmitoyltransferase I activity in Hep2 cells. Biochem Mol Biol Int 1998; 45: 331-6.
72. Pardini RS. Nutritional intervention with omega-3 fatty acids enhances tumor response to anti-neoplastic agents. Chem Biol Interact 2006; 162: 89-105.
73. Biondo PD, Brindley DN, Sawyer MB, Field CJ. The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. J Nutr Biochem 2008; 19: 787-96.
74. Madhavi N, Das UN. Effect of n-6 and n-3 fatty acids on the survival of vincristine sensitive and resistant human cervical carcinoma cells in vitro. Cancer Lett 1994 29; 84: 31-41.
75. Das UN, Madhavi N, Sravan Kumar G, Padma M, Sangeetha P. Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites? Prostaglandins Leukot Essent Fatty Acids 1998; 58: 39-54.
76. Germain E, Chajès V, Cognault S, Lhuillery C, Bougnoux P. Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Int J Cancer 1998; 75: 578-83.
77. Vibet S, Goupille C, Bougnoux P, Steghens JP, Goré J, Mahéo K. Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 2008; 44: 1483-91.
78. Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 2005; 13: 5043-54.
79. Bradley MO, Swindell CS, Anthony FH, et al. Tumor targeting by conjugation of DHA to paclitaxel. J Control Release 2001; 74: 233-6.
80. Wolff AC, Donehower RC, Carducci MK, et al. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 2003; 9: 3589-97.
81. Harries M, O'Donnell A, Scurr M, et al. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. Br J Cancer 2004; 91: 1651-5.
82. Jones RJ, Hawkins RE, Eatock MM, et al. A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol 2008; 61: 435-41.
83. Fracasso PM, Picus J, Wildi JD, et al. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol 2009; 63: 451-8.
84. Wang Y, Li L, Jiang W, Larrick JW. Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate. Bioorg Med Chem 2005; 13: 5592-9.
85. Siddiqui RA, Zerouga M, Wu M, et al. Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Res 2005; 7: R645-54.
86. Wang Y, Li L, Jiang W, Yang Z, Zhang Z. Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg Med Chem Lett 2006; 16: 2974-7.
87. Kuznetsova L, Chen J, Sun L, et al. Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg Med Chem Lett 2006; 16: 974-7
88. Huan ML, Zhou SY, Teng ZH, et al. Conjugation with alpha-linolenic acid improves cancer cell uptake and cytotoxicity of doxorubicin. Bioorg Med Chem Lett 2009; 19: 2579-84.